Author pages are created from data sourced from our academic publisher partnerships and public sources.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
BACKGROUND Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We… Expand
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique… Expand
Symptom prevalence in patients with incurable cancer: a systematic review.
- S. Teunissen, Wendy Wesker, C. Kruitwagen, H. J. de Haes, E. Voest, A. de Graeff
- Journal of pain and symptom management
- 1 July 2007
The suffering of patients with incurable cancer is determined to a large degree by the presence and intensity of the symptoms of their disease. Knowledge of symptom prevalence is important for… Expand
Inhibition of angiogenesis in vivo by interleukin 12.
- E. Voest, B. Kenyon, M. O'reilly, G. Truitt, R. D'Amato, J. Folkman
- Journal of the National Cancer Institute
- 19 April 1995
BACKGROUND In previous animal studies, interleukin 12 (IL 12) was shown to inhibit the growth of a wide spectrum of tumors in vivo but to have no direct effect on tumor cells in vitro. Also, contrary… Expand
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
- L. Ellis, D. Bernstein, +12 authors L. Schnipper
- Journal of clinical oncology : official journal…
- 20 April 2014
See accompanying editorial on page 1186 Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, TX; David S. Bernstein and Richard L. Schilsky, American Society of Clinical Oncology,… Expand
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Several hypotheses have been proposed to explain how antiangiogenic drugs enhance the treatment efficacy of cytotoxic chemotherapy, including impairing the ability of chemotherapy-responsive tumors… Expand
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.
- M. Kuroki, E. Voest, +8 authors A. P. Adamis
- Biology, Medicine
- The Journal of clinical investigation
- 1 October 1996
Elevated vascular endothelial growth factor (VEGF) levels are required for ocular and tumor angiogenesis in animal models. Ischemic hypoxia is strongly correlated with increased VEGF expression in… Expand
A model of angiogenesis in the mouse cornea.
- B. Kenyon, E. Voest, C. C. Chen, E. Flynn, J. Folkman, R. D'Amato
- Biology, Medicine
- Investigative ophthalmology & visual science
- 1 July 1996
PURPOSE The study of angiogenesis depends on reliable and reproducible models for the stimulation of a neovascular response. The purpose of this research was to develop such a model of angiogenesis… Expand
Genetic analysis of von Hippel‐Lindau disease
- Morgan Nordstrom-O'Brien, R. B. van der Luijt, +6 authors R. Giles
- Medicine, Biology
- Human mutation
- 1 May 2010
Mutations in the von Hippel‐Lindau (VHL) gene are responsible for VHL disease, congenital polycythemia, and are found in many sporadic tumor types as well. Reports of VHL mutations are dispersed… Expand
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients.
- L. Beerepoot, N. Mehra, J. Vermaat, B. Zonnenberg, M. Gebbink, E. Voest
- Annals of oncology : official journal of the…
BACKGROUND There is accumulating evidence from preclinical studies that circulating endothelial cells (CECs) play an important role in neovascularization and tumor growth. The role of CECs in human… Expand